RATIONALE: Creatine is thought to be involved in the spatial and temporal buffering of ATP in energetic organs such as heart and skeletal muscle. Creatine depletion affects force generation during maximal stimulation, while reduced levels of myocardial creatine are a hallmark of the failing heart, leading to the widely held view that creatine is important at high workloads and under conditions of pathological stress. OBJECTIVE: We therefore hypothesised that the consequences of creatine-deficiency in mice would be impaired running capacity, and exacerbation of heart failure following myocardial infarction. METHODS AND RESULTS: Surprisingly, mice with whole-body creatine deficiency due to knockout of the biosynthetic enzyme (guanidinoacetate N-methyltransferase [GAMT]) voluntarily ran just as fast and as far as controls (>10 km/night) and performed the same level of work when tested to exhaustion on a treadmill. Furthermore, survival following myocardial infarction was not altered, nor was subsequent left ventricular (LV) remodelling and development of chronic heart failure exacerbated, as measured by 3D-echocardiography and invasive hemodynamics. These findings could not be accounted for by compensatory adaptations, with no differences detected between WT and GAMT(-/-) proteomes. Alternative phosphotransfer mechanisms were explored; adenylate kinase activity was unaltered, and although GAMT(-/-) hearts accumulated the creatine precursor guanidinoacetate, this had negligible energy-transfer activity, while mitochondria retained near normal function. CONCLUSIONS: Creatine-deficient mice show unaltered maximal exercise capacity and response to chronic myocardial infarction, and no obvious metabolic adaptations. Our results question the paradigm that creatine is essential for high workload and chronic stress responses in heart and skeletal muscle.
RATIONALE: Creatine is thought to be involved in the spatial and temporal buffering of ATP in energetic organs such as heart and skeletal muscle. Creatine depletion affects force generation during maximal stimulation, while reduced levels of myocardial creatine are a hallmark of the failing heart, leading to the widely held view that creatine is important at high workloads and under conditions of pathological stress. OBJECTIVE: We therefore hypothesised that the consequences of creatine-deficiency in mice would be impaired running capacity, and exacerbation of heart failure following myocardial infarction. METHODS AND RESULTS: Surprisingly, mice with whole-body creatine deficiency due to knockout of the biosynthetic enzyme (guanidinoacetate N-methyltransferase [GAMT]) voluntarily ran just as fast and as far as controls (>10 km/night) and performed the same level of work when tested to exhaustion on a treadmill. Furthermore, survival following myocardial infarction was not altered, nor was subsequent left ventricular (LV) remodelling and development of chronic heart failure exacerbated, as measured by 3D-echocardiography and invasive hemodynamics. These findings could not be accounted for by compensatory adaptations, with no differences detected between WT and GAMT(-/-) proteomes. Alternative phosphotransfer mechanisms were explored; adenylate kinase activity was unaltered, and although GAMT(-/-) hearts accumulated the creatine precursor guanidinoacetate, this had negligible energy-transfer activity, while mitochondria retained near normal function. CONCLUSIONS: Creatine-deficient mice show unaltered maximal exercise capacity and response to chronic myocardial infarction, and no obvious metabolic adaptations. Our results question the paradigm that creatine is essential for high workload and chronic stress responses in heart and skeletal muscle.
Authors: Matthias Nahrendorf; Jörg U Streif; Karl-Heinz Hiller; Kai Hu; Peter Nordbeck; Oliver Ritter; David Sosnovik; Lisa Bauer; Stefan Neubauer; Peter M Jakob; Georg Ertl; Matthias Spindler; Wolfgang R Bauer Journal: Am J Physiol Heart Circ Physiol Date: 2006-01-13 Impact factor: 4.733
Authors: Ashish Gupta; Ashwin Akki; Yibin Wang; Michelle K Leppo; V P Chacko; D Brian Foster; Viviane Caceres; Sa Shi; Jonathan A Kirk; Jason Su; Shenghan Lai; Nazareno Paolocci; Charles Steenbergen; Gary Gerstenblith; Robert G Weiss Journal: J Clin Invest Date: 2011-12-27 Impact factor: 14.808
Authors: Jonathan P Brennan; Richard Southworth; Rodolfo A Medina; Sean M Davidson; Michael R Duchen; Michael J Shattock Journal: Cardiovasc Res Date: 2006-07-29 Impact factor: 10.787
Authors: Imanuel Lerman; Brooke C Harrison; Kalev Freeman; Timothy E Hewett; David L Allen; Jeffrey Robbins; Leslie A Leinwand Journal: J Appl Physiol (1985) Date: 2002-06
Authors: Craig A Lygate; Imre Hunyor; Debra Medway; Joe P de Bono; Dana Dawson; Julie Wallis; Liam Sebag-Montefiore; Stefan Neubauer Journal: J Mol Cell Cardiol Date: 2008-10-04 Impact factor: 5.000
Authors: Heinrich Taegtmeyer; Martin E Young; Gary D Lopaschuk; E Dale Abel; Henri Brunengraber; Victor Darley-Usmar; Christine Des Rosiers; Robert Gerszten; Jan F Glatz; Julian L Griffin; Robert J Gropler; Hermann-Georg Holzhuetter; Jorge R Kizer; E Douglas Lewandowski; Craig R Malloy; Stefan Neubauer; Linda R Peterson; Michael A Portman; Fabio A Recchia; Jennifer E Van Eyk; Thomas J Wang Journal: Circ Res Date: 2016-03-24 Impact factor: 17.367